Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Homozygous Familial Hypercholesterolemia

Cardiovascular

Homozygous Familial Hypercholesterolemia Clinical Trials

Also called HoFH, Homozygous FH, Severe Familial Hypercholesterolemia, Familial Hypercholesterolemia Type II

Homozygous Familial Hypercholesterolemia is one of the most severe genetic cholesterol disorders. People with HoFH have genetic mutations that severely impair their ability to remove LDL (bad) cholesterol from the blood, resulting in cholesterol levels 4 times higher than normal. This causes premature and aggressive atherosclerosis, with coronary artery disease developing in childhood rather than adulthood. Cholesterol accumulates visibly in tendons and under the skin.

In plain words, homozygous familial hypercholesterolemia is a genetic condition where the body cannot clear bad cholesterol from the blood. Cholesterol levels are very high from birth, leading to heart disease early in life and fatty lumps on tendons and skin.

Get an email when new Homozygous Familial Hypercholesterolemia trials open or the FDA decides. Get alerts

Homozygous Familial Hypercholesterolemia

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 5 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines11

Evkeeza · Atorvastatin Calcium · Caduet · Juxtapid · Leqvio · 6 more

Homozygous Familial Hypercholesterolemia has 11 FDA-approved medicines, 12 open or active clinical trials (11 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Homozygous Familial Hypercholesterolemia

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Homozygous Familial Hypercholesterolemia

Traditional treatment relied on cholesterol-lowering medications like statins combined with LDL apheresis, a procedure that filters cholesterol from blood during dialysis-like sessions. While these approaches improved survival, patients still faced significant cardiovascular risk. Newer medications work through different mechanisms. Evinacumab (Evkeeza) targets ANGPTL3, a protein that regulates cholesterol levels, and provides additional LDL reduction when added to standard therapies.

Keep reading about Homozygous Familial Hypercholesterolemia

Early, aggressive treatment is critical to prevent heart attacks and extend life. Many patients now survive longer with better quality of life, though lifelong treatment is required.

What are the symptoms of Homozygous Familial Hypercholesterolemia?

These are common symptoms of Homozygous Familial Hypercholesterolemia, and how strong they are varies from person to person.

  • Extremely high LDL cholesterol (usually above 400mg/dL, often 500 to 1,000mg/dL)
  • Fatty lumps on tendons, especially the Achilles tendon and hand tendons
  • Yellowish deposits around eyelids (xanthelasmas)
  • Early signs of heart disease or heart attack in childhood
  • Coronary artery disease symptoms in childhood or early adulthood
  • Grayish ring around the cornea (corneal arcus)

Who gets Homozygous Familial Hypercholesterolemia?

HoFH occurs when a person inherits cholesterol-raising gene mutations from both parents. Symptoms begin in childhood, with cholesterol deposits visible early and heart disease risk emerging before age 10 without treatment. The condition affects males and females equally and can occur in any ethnic background, though it is more common in certain populations with founder mutations.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Homozygous Familial Hypercholesterolemia?

There are currently 11 FDA-approved medications for Homozygous Familial Hypercholesterolemia.

Atorvastatin Calcium
atorvastatin calcium, film coated
Preferred Pharmaceuticals Inc.
Search
Caduet
amlodipine and atorvastatin
Pfizer Laboratories Div Pfizer Inc
Search
evinacumab-dgnb
Juxtapid
lomitapide mesylate
Chiesi USA, Inc.
Search
Leqvio
inclisiran
Novartis Pharmaceuticals Corporation
Search
Praluent
alirocumab
Regeneron Pharmaceuticals, Inc.
Search
Repatha
evolocumab
Amgen USA Inc.
Search
Rosuvastatin calcium
rosuvastatin calcium
REMEDYREPACK INC.
Search
Vytorin
ezetimibe and simvastatin
Zetia
ezetimibe
Organon LLC
Search
Zocor
simvastatin
Organon LLC
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Homozygous Familial Hypercholesterolemia treatment

Charity funds and drugmaker programs for Homozygous Familial Hypercholesterolemia, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Homozygous Familial Hypercholesterolemia

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Homozygous Familial Hypercholesterolemia resources

Reputable organizations and medical references for learning more about Homozygous Familial Hypercholesterolemia, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Homozygous Familial Hypercholesterolemia

Use this Homozygous Familial Hypercholesterolemia clinical trial finder to see the 11 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 8 test a treatment and 4 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

12 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Recently updatedNCT07473843

Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Intervention: Zodasiran

Sponsor: Arrowhead Pharmaceuticals

This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to <18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and low-density lipoprotein cholesterol (LDL-C) ≥116 milligram...

Ages 12 Years to 17 Years3 locations
Expected to start Oct 2026Updated 3 weeks agoEst. Jul 2028 (~1y 8m)
RecruitingTreatment trialRecently updatedNCT07470723

The ORIGIN-FH Study

Intervention: Screening for FH

Sponsor: University of Wisconsin, Madison

The goal of this clinical trial is to identify different types of Familial Hypercholesterolemia (FH) in infants and newborns. Participants will:

* undergo a cheek swab for genetic testing (parents only)

* have 5 blood samples collected

Ages 18 Years+1 location
Started Feb 2026Updated 1 month agoEst. Feb 2029 (~2y 2m)
RecruitingTreatment trialPhase 1Recently updatedNCT07491172

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Intervention: CTX310

Sponsor: CRISPR Therapeutics AG

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.

Ages 18 Years to 75 Years
Started Jun 2024Updated 2 months agoEst. Jun 2027 (~7 months)
RecruitingTreatment trialPhase 3Recently updatedNCT05682378

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Intervention: Inclisiran

Sponsor: Novartis Pharmaceuticals

The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 (CKJX839C12301), ORION-13 (CKJX839C12302), ORION-20 (CKJX839C12303) or ORION-19 (CKJX839C12304) studies.

Ages 2 Years to 100 Years
Started Feb 2023Updated 2 months agoEst. Mar 2032 (~5y 4m)
RecruitingTreatment trialEarly Phase 1Recently updatedNCT06125847

NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia

Intervention: NGGT006

Sponsor: First Affiliated Hospital Xi'an Jiaotong University

This is an early phase 1, open-label, single-center, dose-escalation, pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in homozygous familial hypercholesterolemia (HoFH) patients with LDLR mutations. NGGT006 is an adeno-associated viral (AAV) ...

Ages 12 Years to 55 Years1 location
Started Oct 2023Updated 2 months agoEst. Mar 2027 (~4 months)
Find Homozygous Familial Hypercholesterolemia trials near you, ranked by distance →
Active trial locations16 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+8 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Early Phase 1
Phase 1
Phase 2
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Homozygous Familial Hypercholesterolemia trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Homozygous Familial Hypercholesterolemia foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Homozygous Familial Hypercholesterolemia patient communities

Facebook groups, Reddit communities and YouTube channels where Homozygous Familial Hypercholesterolemia patients, caregivers and advocacy groups talk.

Companies developing Homozygous Familial Hypercholesterolemia treatments

Drugmakers that list Homozygous Familial Hypercholesterolemia in their rare disease portfolio, 11 in all.

Questions people ask about Homozygous Familial Hypercholesterolemia